-
AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer
•
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III study for its PD-1xTIGIT bispecific antibody (BsAb) rilvegostomig in combination with chemotherapy for patients with biliary tract cancer (BTC) following surgical resection. The double-blind, placebo-controlled, global trial aims to assess the efficacy and tolerability of…
-
Lee’s Pharmaceutical’s Socazolimab Becomes China’s First PD-L1 mAb for Cervical Cancer
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured in-licensed rights for socazolimab, a treatment for recurrent-metastatic cervical cancer, according to the National Medical Products Administration (NMPA) website. This drug marks the first programmed-death ligand 1 (PD-L1) monoclonal antibody (mAb) for cervical cancer in China. Socazolimab, originally developed by US-based Sorrento…
-
Zhiyi Biotechnology and Henlius Biotech Partner to Develop Novel Drug Products and Platforms
•
Guangzhou-based Zhiyi Biotechnology has entered into a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm. The collaboration aims to develop innovative drug products and technology platforms, with a particular focus on the advancement of engineered bacterial drugs and new functional strains. The joint efforts will…
-
FDA Rejects MSD’s Gefapixant for Chronic Cough Treatment Over Efficacy Concerns
•
The US Food and Drug Administration (FDA) has declined to approve a filing from Merck, Sharp & Dohme (MSD; NYSE: MRK) for its P2X3 receptor antagonist, gefapixant, which was being considered as a treatment for refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. The rejection was due…
-
Shanghai Novopathway and PONY Biomedicine Join Forces for Pre-Clinical Drug Development Platform
•
Shanghai Novopathway Biotechnology, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm PONY Biomedicine to co-develop a comprehensive one-stop service platform for small and large molecule drugs in the pre-clinical stage. This collaboration aims to offer competitive technical services and solutions to biopharmaceutical clients on…
-
GSK Secures Exclusive Rights to Hansoh’s ADC Candidate HS-20093 in New Licensing Deal
•
GlaxoSmithKline (GSK; NYSE: GSK), a major UK pharmaceutical company, has entered into its second licensing agreement with Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) within two months, focusing once again on an antibody-drug conjugate (ADC) product candidate. Hansoh has granted GSK exclusive rights to develop, manufacture, and commercialize its novel…
-
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
•
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma’s in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed. Eltrombopag…
-
Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices, has announced the completion of patient enrollment in a multi-center clinical study for its ZENFLEX peripheral vascular stent system in Germany. The study has reached its target of 100 patients. This prospective, multi-center, single-arm study…
